Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success

Published by: Spectra Intelligence

Published: Nov. 1, 2006 - 367 Pages

Table of Contents

Contents List

List of Tables

List of Figures

List of Abbreviations

Executive Summary

Objectives of the Report

Research Methodology

CHAPTER 1. PRECLINICAL CHALLENGES IN THE DEVELOPMENT OFNEW PHARMACOLOGICAL AGENTS TO TREAT CANCER

1.1 Tumour Biology: Oncogenes and Tumour Suppressor Genes

1.2 Genomic Instability and Neoplastic Transformation

1.3 Mechanisms of Drug Resistance

1.4 Identification of Appropriate Molecular/Cancer Targets for Research and Development

1.4.1 DNA Binding Targets

1.4.2 Oncogenes and Tumour Suppressor Genes as Targets

1.4.3 Receptor Kinase Pathways as Targets

1.4.4 Hormonal Receptor Targets

1.4.5 Invasion, Metastasis and Angiogenesis Pathways as Targets

1.4.6 Immunological Targets

1.4.7 Methods for the Identification of Genes and Proteins of Interest

1.5 Current Models of Successful New Cancer Treatment Approaches

1.6 Limitations to Current Therapeutic Approaches

CHAPTER 2. TOOLS FOR PRECLINICALDRUG DEVELOPMENT

2.1 Preclinical Drug Discovery Approaches

2.1.1 Tumour Targeted Approaches: General Considerations

2.1.2 Gene Targeted Therapeutic Approaches

2.1.2.1 Small Molecule Inhibitors

2.1.2.2 Inhibitory RNAs

2.1.2.3 Nanoparticle Technology

2.1.2.4 Immunotherapy: Human Monoclonal Antibodies

2.1.2.5 Recombinant Genetically Engineered Therapeutic Viruses

2.1.3 Biomarkers

2.1.4 Sources of Potential Anticancer Agents for Preclinical Assessment: Non-Gene Targeted Approaches

2.1.5 Medicinal Chemistry: Role in Drug Discovery and Preclinical Therapeutic Assessment

2.2 Preclinical Assessment Tools: General Parameters of Preclinical Response

2.2.1 Preclinical Assessment: Lead Drug Candidate Selection Process

2.2.2 Primary and Secondary Screens: Lead Optimisation

2.3 Types of Preclinical Assessment Models

2.3.1 In Vitro Cell Culture Assays

2.3.2 Biochemical and Histological Methods Used for In-Vitro Assessment

2.3.3 In Vivo Assessment Models

2.3.3.1 In Vivo Preclinical Assessment: Parameters of Preclinical Response

2.4 Imaging Tools for Preclinical Assessment

2.4.1 Tumour Imaging

2.4.2 Imaging Technologies: Preclinical Therapeutic Applications

2.4.3 Pharmacodynamic Applications of Imaging Technologies

2.5 Evaluation of Potential Predictive Clinical Value of Preclinical Assessment Tools

CHAPTER 3. CANCER IMMUNOTHERAPY

3.1 Preclinical Approaches to Active Immunotherapy: General Considerations

3.2 Active Immunotherapy Protocols in Preclinical Development

3.3 Therapeutic Cancer Vaccines in Preclinical Development

3.3.1 Individualised Patient Tumour Vaccines

3.3.2 Therapeutic Virus Vaccines

3.3.3 Protein/Peptide Cancer Vaccines

3.3.4 Dendritic Cell Vaccines

3.4 Artificial Immunostimulatory Antibodies

3.5 Novel Antigenic Tumour Targets in Preclinical Drug Development

3.5.1 Telomerase

3.5.2 Tumour Stem Cell Targets in Preclinical Development

3.5.3 Immunostimulatory Cytokine Therapeutics in Preclinical Development

3.6 Preclinical Approaches to Passive Immunotherapy

3.6.1 Monoclonal Antibody Therapeutics

3.6.2 Mouse Monoclonal Antibodies

3.6.3 Humanised and Fully Human Monoclonal Antibodies

3.6.3.1 Selected Companies Developing Preclinical/Early Clinical Monoclonal Antibody Cancer Therapeutics

3.7 Other Antigen-Targeted Therapies: Significant Highlights

3.8 Genetically Engineered Cytolytic Viruses - ‘Smart Viruses’

3.9 Current Challenges to the Development of Effective Immotherapeutic Approaches to Cancer

CHAPTER 4. TARGETED CANCER THERAPEUTICS: SMALLMOLECULE INHIBITORS IN PRECLINICAL DEVELOPMENT

4.1 Strategic Development of Novel Anticancer Agents

4.2 Major Cancer Pathway Sources of Small Molecule Therapeutic Targets: PTEN/PI3K/Akt

4.3 RAS Activated Cell Proliferation Pathway: Important Therapeutic Targets

4.4 Small Molecule Therapeutic Targets: Wnt/Beta-Catenin Pathway

4.5 Other Dysregulated Cell Processes: Potential Therapeutic Interactions

4.5.1 Sonic Hedgehog Pathway

4.5.2 Transforming Growth Factor-Beta

4.5.3 Ubiquitin Proteasome Pathway Targets

4.5.4 Additional Kinase Inhibitors in Preclinical Development

4.5.4.1 Small Molecule Protein Tyrosine Kinase Inhibitors

4.5.4.2 Serine/Threonine Kinase Inhibitors

4.5.5 Small Molecule Inhibitors of Angiogenesis in Development

4.5.6 Small Molecule Inhibitors of Heat Shock Proteins in Development

4.5.7 Small Molecule Immunotherapeutics

4.6 Future Challenges to the Development of Small Molecule Cancer Therapeutics

CHAPTER 5. HORMONAL AGENTS AS THERAPEUTIC ONCOLOGYTARGETS

5.1 The Steroid Receptor Family

5.1.1 Tamoxifen as an Exemplary Clinical Compound in Current Use

5.1.2 Challenges to Current Clinical Treatment Approaches

5.1.3 The Steroid Superfamily of Receptors

5.1.3.1 Oestrogen Receptor as a Therapeutic Target

5.1.3.2 Selective Oestrogen Receptor Modulators

5.1.3.3 Aromatase Inhibitors

5.1.3.4 The Progesterone Receptor as a Therapeutic Target

5.1.3.5 The Androgen Receptor as a Therapeutic Target

5.1.3.6 Retinoic Acid Receptors and Retinoid X Receptors as Therapeutic Targets

5.1.3.7 Peroxisome Proliferator Activated Receptor as a Therapeutic Target

5.2 Summary of Hormonal Agents in Preclinical Trials

CHAPTER 6. PRECLINICAL ANGIOGENIC CANCER TARGETS

6.1 Angiogenesis Associated with Malignancies

6.2 Characteristics of Tumour Vasculature

6.3 Pro-angiogenic Molecules as Targets

6.3.1 Fibroblast Growth Factor

6.3.2 Vascular Endothelial Growth Factor

6.3.3 Platelet-Derived Growth Factor

6.3.4 Epidermal Growth Factor, Transforming Growth Factor-Alpha, and Epidermal Growth Factor Receptor

6.3.5 Tumour Necrosis Factor-Alpha

6.3.6 Transforming Growth Factor-Beta

6.3.7 Hypoxia-Inducible Factor-1

6.3.8 Angiogenin

6.3.9 Angiopoietin

6.4 Endogenous Inhibitors of Angiogenesis

6.4.1 Endogenous Angiogenesis Inhibitors Derived from Matrix

6.4.1.1 Arresten

6.4.1.2 Canstatin

6.4.1.3 Endostatin

6.4.1.4 Thrombospondin

6.4.1.5 Tumstatin

6.4.1.6 Endorepellin

6.4.2 Endogenous Angiogenesis Inhibitors of Nonmatrix Origin

6.4.2.1 Angiostatin

6.4.2.2 Interferons

6.4.2.3 Interleukins

6.4.2.4 Platelet Factor-4

6.4.2.5 16kDa Prolactin Fragment (16K PRL)

6.4.2.6 Tissue Inhibitors of Matrix Metalloproteinases

6.4.2.7 Troponin I

6.4.2.8 Vasostatin

6.5 Miscellaneous Angiogenesis Targets

6.5.1 Copper

6.5.2 Calcium Channel Modulators

6.6 Monoclonal Antibodies and Angiogenesis

6.6.1 Mechanism of Action

6.6.2 Challenges Encountered in the Use of Monoclonal Antibody Therapy

6.7 Receptor Tyrosine Kinases as Potential Cancer Therapeutic Targets

6.8 Viral Vectors/Gene Therapy Approaches

6.9 Small Molecule Inhibitors

6.10 Preclinical Angiogenesis Agents by Drug Target

CHAPTER 7. PRECLINICAL PROSPECTS FOR HAEMATOPOIETIC CANCERS

7.1 Chemotherapy: Historical Perspectives and Treatment Milestones

7.2 The Leukaemias: Overview

7.2.1 Acute Myeloid Leukaemia

7.2.2 Chronic Myeloid Leukaemia

7.2.3 Acute Lymphoblastic Leukaemia

7.2.3.1 Paediatric Leukaemias

7.2.3.2 Acute Lymphoblastic Leukaemia - Adult

7.2.4 Chronic Lymphocytic Leukaemia

7.3 The Lymphomas

7.3.1 Hodgkin’s Disease

7.3.2 NonHodgkin’s Lymphoma

7.3.2.1 Diffuse Large B-Cell Lymphoma

7.3.2.2 Follicular Lymphoma

7.3.2.3 Burkitt’s Lymphoma

7.3.3 Current Treatment Regimens for Lymphoma

7.4 Genes Linked to Leukaemia and Lymphoma: Basis for Rational Drug Design

7.4.1 Genetic Mechanisms Implicated in the Genesis of Leukaemias and Lymphomas: New Paradigms

7.4.1.1 Genetic Origins of Acute Myeloid Leukaemia

7.4.1.2 Genetic Origins of Chronic Myeloid Leukaemia

7.4.1.3 Genetics Origins of Acute Lymphoblastic Leukaemia

7.4.1.4 Genetic Origins of Chronic Lymphocytic Leukaemia

7.4.1.5 Genetics and Other Types of Leukaemia

7.4.2 Genetic Origins of Lymphoma

7.4.2.1 B-Cell NonHodgkin’s Lymphoma/Diffuse Large B-Cell Lymphoma

7.4.2.2 Follicular NonHodgkin’s Lymphoma

7.5 New Treatment Approaches to Leukaemia and Lymphoma in Preclinical Development

7.5.1 Promising Agents for Acute Myeloid Leukaemia

7.5.2 Promising Preclinical Agents for Chronic Myeloid Leukaemia

7.5.3 Promising Preclinical Agents for Acute Lymphoblastic Leukaemia

7.5.4 Promising Preclinical Agents for Chronic Lymphocytic Leukaemia

7.5.5 Promising Treatment Approaches with Potential Broad-Spectrum Anti-Leukaemic Activity

7.5.6 Promising Treatment Approaches in Development for Other Leukaemias

Chapter 8. PRECLINICAL APPROACHES TO THE TREATMENT OF SOLID TUMOURMALIGNANCIES

8.1 General Therapeutic Parameters of Solid Tumour Malignancies

8.2 Solid Tumour Biology: Implications for Preclinical Therapeutic Approaches

8.3 Chemotherapy Drugs in Preclinical/Early Stage Development with Broad Spectrum Applications for the Treatment of Solid Tumour Malignancies

8.4 Recent Advances in Solid Tumour Immunotherapy

8.5 Novel Genes Implicated in Solid Tumour Malignancies

8.6 Important Advances in Preclinical Therapeutics for the Most Common Solid Tumour Malignancies

8.6.1 Brain Tumours

8.6.1.1 Important Recent Preclinical Research Findings

8.6.2 Breast Cancer

8.6.2.1 Important Recent Preclinical Research Findings

8.6.3 Colon Cancer

8.6.3.1 Important Recent Preclinical Research Findings

8.6.4 Lung Cancer

8.6.4.1 Important Recent Preclinical Research Findings

8.6.5 Melanoma

8.6.5.1 Important Recent Preclinical Research Findings

8.6.6 Ovarian Cancer

8.6.6.1 Important Recent Preclinical Research Findings

8.6.7 Prostate Cancer

8.6.7.1 Important Recent Preclinical Research Findings

8.6.8 Urinary Tract Cancers

8.6.8.1 Important Recent Preclinical Research Findings

CHAPTER 9. MARKETOUTLOOK FOR THEMOSTPROMISING ANTICANCER DRUGS CURRENTLY IN PRECLINICAL/EARLY STAGE CLINICAL DEVELOPMENT

9.1 Market Assessment for Next Generation Anticancer Therapeutics

9.2 The Global Market Value for Oncology Therapeutics

9.2.1 Best-Selling Oncology Products

9.2.1.1 Leading Multinational Companies and Cancer Drugs

9.3 Research and Market Analysis of the Most Promising Anticancer Agents in Late Stage Preclinical/Early Clinical Stage Development

9.4 Market Outlook for Most Promising Pipeline Oncology Products in Major Therapeutic Categories

9.4.1 Market Outlook for Angiogenesis Inhibitors

9.4.2 Market Outlook for Novel Drug Delivery Formulations

9.4.3 Market Outlook for Targeted Therapeutics

9.4.3.1 Aurora Kinase Inhibitors

9.4.3.2 Growth Factor Receptor Inhibitors

9.4.3.3 Hormonal Therapies

9.4.3.4 Histone Deacetylase Inhibitors

9.4.4 Market Outlook for Nanotechnology Products

9.4.5 Market Outlook for Monoclonal Antibodies

9.4.6 Market Outlook for Second-Generation Drugs

9.4.7 Market Outlook for Promising Anticancer Drugs: Concluding Thoughts

BIBLIOGRAPHIC SOURCES

LIST OF TABLES

Table 1.1 Oncogenes and the Types of Cancers Resulting from Their Activation

Table 1.2 Tumour Suppressor Genes and Cancers that Result from Their Inactivation

Table 1.3 Oncogenes and Tumour Suppressor Genes and the Various Proteins Encoded

Table 2.1 Most Common Preclinical Endpoints Used to Assess Therapeutic Efficacy and Safety

Table 2.2 Comparative Assessment of Imaging Modalities Used to Evaluate In Vivo Pre-clinical Tumour Responses.

Table 3.1 Summary of Individualised Therapeutic Cancer Vaccines in Preclinical/Early Stage Clinical Development

Table 3.2 Tumour Antigen Targets in Preclinical Development

Table 3.3 Genetically Engineered Therapeutic Viruses in Preclinical Development

Table 4.1 Small Molecule Pathway Targeted Inhibitors in Development

Table 5.1 Effects of Selective Oestrogen Receptor Modulators (SERMs) on Various Tissue Types

Table 5.2 Tissues that Express Oestrogen Receptor

Table 5.3 Androgens: Sites of Production and Functions

Table 5.4 Summary of Best Potential Approaches to Steroid Receptor Mediated Malignant Diseases

Table 5.5 Key Advantages and Disadvantages of Oestrogen Receptors as Chemo-therapeutic Targets

Table 5.6 Key Advantages and Disadvantages of Androgen Receptors as Chemo-therapeutic Targets

Table 5.7 Key Advantages and Disadvantages of Retinoid X Receptors and Peroxisome Proliferator Activator Receptors as Chemotherapeutic Targets

Table 5.8 Key Advantages and Disadvantages of Progesterone Receptors as Chemotherapeutic Targets

Table 6.1 Key Physiological Events in the Activation and Resolution Phases of Angiogenesis

Table 6.2 Positive and Negative Regulators of Angiogenesis

Table 6.3 Summary of Preclinical Anticancer Agents by Drug Targets

Table 6.4 Summary of Preclinical Anticancer Agents by Mechanism(s) of Action

Table 7.1 Subtypes of Acute Myeloid Leukaemia

Table 7.2 Revised European and American Lymphoma (REAL) Classification of Leukaemias and Lymphomas

Table 7.3 Genes Implicated in Human Leukaemias

Table 7.4 Genes Implicated in Acute Myeloid Leukaemia: Potential Therapeutic Targets for Preclinical Development

Table 7.5 Genes Identified in Acute Lymphoblastic Leukaemia: Potential Therapeutic Targets for Preclinical Development

Table 7.6 Genes Identified in Chronic Lymphocytic Leukaemia: Potential Therapeutic Targets for Preclinical Development

Table 7.7 Genes Identified in NonHodgkin’s Lymphoma: Potential Therapeutic Targets for Preclinical Development

Table 7.8 Novel Therapeutic Agents in Development for Acute Myeloid Leukaemia

Table 7.9 Promising Therapeutic Agents for Chronic Myeloid Leukaemia in Development

Table 7.10 Novel Therapeutic Agents for Acute and Chronic Lymphocytic Leukaemia in Development

Table 7.11 Novel Treatment Approaches in Development with Broad Spectrum Anti-Leukaemic Activity

Table 7.12 Promising New Treatment Approaches in Development for Lymphoma

Table 7.13 Promising Therapeutic Agents for the Treatment of Haematological Malignancies in Preclinical Development

Table 8.1 Promising Agents with Broad Spectrum Therapeutic Applications in Preclinical/Early Clinical Stage Development

Table 8.2 Important Recently Identified Genes Implicated in Solid Tumour Malignancies

Table 8.3 Major Preclinical Developments in Brain Cancer Therapeutics

Table 8.4 Major Preclinical Developments in Breast Cancer Therapeutics

Table 8.5 Major Preclinical Developments in Colon Cancer Therapeutics

Table 8.6 Major Preclinical Developments in Lung Cancer Therapeutics

Table 8.7 Major Preclinical Developments in Melanoma Therapeutics

Table 8.8 Major Preclinical Developments in Ovarian Cancer Therapeutics

Table 8.9 Major Preclinical Developments in Prostate Cancer Therapeutics

Table 8.10 Promising Agents in Preclinal Development for the Treatment of Solid Tumour Malignancies

Table 9.1 Global Portfolio Revenues and Market Share of Cancer Drugs, 2005 (US$m)

Table 9.2 Summary of Promising Cancer Therapeutics in Preclinical Development by Drug Class

Table 9.3 Summary of Promising Cancer Therapeutics in Phase-I Trials by Drug Class

Table 9.4 Summary of Promising Cancer Therapeutics in Phase-II/II Trials by Drug Class

Table 9.5 Summary of Promising Novel Combination Chemotherapy Approaches in Clinical Trials

LIST OF FIGURES

Figure 1.1 The Cell Cycle

Figure 1.2 DNA Binding Agents used as Chemotherapeutic Interventions in Cancer

Figure 1.3 Growth Factors that Activate Angiogenesis

Figure 1.4 Immunological Agents

Figure 2.1 General Approach to New Drug Development

Figure 2.2 General Approaches to Drug Discovery: Random Versus Rational Drug Design

Figure 2.3 General Categories of Biotechnology Tools Used in Targeted Drug Discovery

Figure 2.4 General Categories of Drug Discovery Tools Used in Targeted Versus Non-Targeted Approaches

Figure 2.5 General Categories of Preclinical Assessment Parameters

Figure 2.6 In Vitro and In Vivo Preclinical Therapeutic Assessment Models

Figure 2.7 Goals of Preclinical Drug Discovery and Assessment Protocols

Figure 3.1 General Areas of Preclinical Cancer Immunotherapy Research

Figure 3.2 Summary of Active Immunotherapy Approaches

Figure 3.3 General Strategy for Producing Recombinant Therapeutic Viral Vaccines

Figure 3.4 Summary of Passive Immunotherapy Approaches to Cancer

Figure 3.5 Construction of Human Monoclonal Antibodies Using the Method of Phage Display

Figure 4.1 General Cell Pathways that Contain Oncogenic Targets for Small Molecule Therapeutic Inhibitors

Figure 4.2. Key Elements in PTEN/PI3K/Akt Signal Transduction Pathway

Figure 4.3 Key Elements in the Ras/Raf/Mek/ERK Signal Transduction Cascade

Figure 4.4 Key Elements of the Wnt/APC/Beta-Catenin Signal Transduction Pathway

Figure 5.1 Steroid Derivatives of Cholesterol

Figure 5.2 Receptors of the Steroid Superfamily Associated with Malignant Diseases

Figure 5.3 Intermediates in the Androgen-Oestrogen Conversion Pathway

Figure 5.4 Intermediates in the Cholesterol-Progesterone Pathway

Figure 6.1 Pro-Angiogenic Molecules Implicated in Cancer Biology

Figure 6.2 Endogenous Angiogenesis Inhibitors Derived from Matrix

Figure 6.3 Endogenous Angiogenesis Inhibitors of Nonmatrix Origin

Figure 6.4 Key Steps in the Conversion of Plasminogen to Angiostatin

Figure 8.1 General Biological Parameters of Solid Tumours Relevant to Therapeutic Design

Figure 9.1 Drug Development Parameters Critical to Market Success

Figure 9.2 Growth Rates of Best-Selling Cancer Drugs, 2005

Figure 9.3 Best-Selling Cancer Drugs, 2005 (US$m)

Figure 9.4 Market Share of the Top 10 Cancer Drugs, 2005 & 2010

Figure 9.5 Leading Oncology Companies by Chemotherapy Portfolio Revenues, 2005 (US$m)

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.